News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Ind-Ra maintains a neutral outlook for healthcare in FY23
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Subscribe To Our Newsletter & Stay Updated
